The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | The role of non-covalent BTK inhibitors in the treatment of non-Hodgkin lymphoma
Fateeha Furqan, MD, Medical College of Wisconsin, Milwaukee, WI, highlights the role of novel non-covalent BTK inhibitors (BTKi), such as pirtobrutinib, in the treatment of non-Hodgkin lymphoma (NHL). Non-covalent BTKis are generally well tolerated and effective and, therefore, do not require a high degree of monitoring upon administration. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
